DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy
DORA：一项针对感染 HIV 的黑人女性的 IIIb 期转换研究，旨在评估从多替拉韦或依非韦伦一线抗逆转录病毒疗法转换为多拉韦林一线抗逆转录病毒疗法后，48 周的体重和代谢变化。
期刊:Hiv Medicine
影响因子:3.2
doi:10.1111/hiv.13711
Woods, Joana; Sokhela, Simiso; Akpomiemie, Godspower; Bosch, Bronwyn; Möller, Karlien; Bhaskar, Esther; Kruger, Chelsea; Manentsa, Ncomeka; Tom, Noxolo; Macholo, Philadelphia; Chandiwana, Nomathemba; Hill, Andrew; Moorhouse, Michelle; Venter, Willem D F
